A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations

Protocol: 
AAAO7704
Phase: 
I

A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations

The primary purpose of this research study is to assess how safe and well tolerated the study drug, IDH305, is when given to patients who have advanced tumors that harbor IDH1R132 mutations. Pre-clinical data suggest the importance of these mutations in maintaining cancer. The hypothesis of this research study is inhibiting the mutant IDH1 mutation in these tumors will result in anti-tumor activity.

Are you Eligible? (Inclusion Criteria)

1. Patients must have documented IDH1R132-mutant tumors.
2. Disease that has progressed since last prior therapy and for which there is no curative therapy.
3. For glioma patients, images from the two most recent brain scans must be available.
4. Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients).

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States